HUP0102473A3 - Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases - Google Patents

Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Info

Publication number
HUP0102473A3
HUP0102473A3 HU0102473A HUP0102473A HUP0102473A3 HU P0102473 A3 HUP0102473 A3 HU P0102473A3 HU 0102473 A HU0102473 A HU 0102473A HU P0102473 A HUP0102473 A HU P0102473A HU P0102473 A3 HUP0102473 A3 HU P0102473A3
Authority
HU
Hungary
Prior art keywords
combination
proliferative diseases
antineoplastic drugs
treating proliferative
benzocycloheptapyridine
Prior art date
Application number
HU0102473A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0102473(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of HUP0102473A2 publication Critical patent/HUP0102473A2/hu
Publication of HUP0102473A3 publication Critical patent/HUP0102473A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0102473A 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases HUP0102473A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US14352998A 1998-08-28 1998-08-28
US18196998A 1998-10-29 1998-10-29
PCT/US1998/026224 WO1999032114A1 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Publications (2)

Publication Number Publication Date
HUP0102473A2 HUP0102473A2 (hu) 2002-01-28
HUP0102473A3 true HUP0102473A3 (en) 2003-07-28

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102473A HUP0102473A3 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Country Status (25)

Country Link
EP (1) EP1041985B1 (hu)
JP (1) JP4502503B2 (hu)
KR (1) KR100700907B1 (hu)
CN (1) CN1129431C (hu)
AR (1) AR017440A1 (hu)
AT (1) ATE317697T1 (hu)
AU (1) AU756762B2 (hu)
BR (1) BR9814419A (hu)
CA (1) CA2315693C (hu)
CL (1) CL2007001889A1 (hu)
CO (1) CO5080764A1 (hu)
CZ (1) CZ298511B6 (hu)
DE (1) DE69833509T2 (hu)
DK (1) DK1041985T3 (hu)
ES (1) ES2255196T3 (hu)
HU (1) HUP0102473A3 (hu)
IL (1) IL136462A0 (hu)
MY (1) MY137303A (hu)
NO (1) NO326832B1 (hu)
NZ (1) NZ504928A (hu)
PE (1) PE20000042A1 (hu)
PT (1) PT1041985E (hu)
SK (1) SK285584B6 (hu)
TW (1) TW581763B (hu)
WO (1) WO1999032114A1 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
JP2003513940A (ja) * 1999-11-09 2003-04-15 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） ヘテロ三量体ｇタンパク質情報の伝達抑制剤と他の抗癌剤とからなる、癌の処置において治療の目的に使用する製品
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
EP1261348A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
CA2397690A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
WO2001064198A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
JP2003525246A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
CA2397253A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
EP1263437A2 (en) * 2000-02-29 2002-12-11 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
WO2002064142A1 (en) * 2001-02-15 2002-08-22 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
BR0214564A (pt) * 2001-11-30 2004-11-09 Schering Corp Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos
CN1849122A (zh) * 2001-12-03 2006-10-18 先灵公司 Fpt抑制剂与至少两种抗肿瘤药在治疗癌症中的用途
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
AU665341B2 (en) * 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
EP0856315B1 (en) * 1995-08-09 2005-08-24 Banyu Pharmaceutical Co., Ltd. Protein-farnesyltransferase inhibitors in combination with hmgcoa-reductase-inhibitors for the treatment of aids
WO1997023478A1 (en) * 1995-12-22 1997-07-03 Schering Corporation Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
JP3737518B2 (ja) * 1996-03-12 2006-01-18 ピージー−ティーエックスエル カンパニー， エル．ピー． 水溶性パクリタキセルプロドラッグ
AU715604B2 (en) * 1996-04-03 2000-02-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US20020034725A1 (en) * 1996-04-15 2002-03-21 W. Gillies Mckenna Sensitization of cells to radiation and and chemotherapy
EP0952842A2 (en) * 1996-04-18 1999-11-03 Merck & Co., Inc. A method of treating cancer
EP0934270A1 (en) * 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
DE69734785T2 (de) * 1997-01-29 2006-08-03 Picker Medical Systems, Ltd. Vorherbestimmung zur verfolgung der optimalen kontrastmittelkonzentration
ATE361668T1 (de) * 1997-02-18 2007-06-15 Canji Inc Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung

Also Published As

Publication number Publication date
MY137303A (en) 2009-01-30
NO326832B1 (no) 2009-02-23
NO20003229L (no) 2000-08-22
TW581763B (en) 2004-04-01
AU1907299A (en) 1999-07-12
EP1041985A1 (en) 2000-10-11
CA2315693C (en) 2010-11-30
JP4502503B2 (ja) 2010-07-14
DE69833509T2 (de) 2006-10-26
DK1041985T3 (da) 2006-06-19
ATE317697T1 (de) 2006-03-15
CZ298511B6 (cs) 2007-10-24
IL136462A0 (en) 2001-06-14
CN1129431C (zh) 2003-12-03
DE69833509D1 (de) 2006-04-20
SK8982000A3 (en) 2001-04-09
PT1041985E (pt) 2006-07-31
BR9814419A (pt) 2000-10-10
CA2315693A1 (en) 1999-07-01
AU756762B2 (en) 2003-01-23
SK285584B6 (sk) 2007-04-05
CL2007001889A1 (es) 2008-01-11
KR20010033452A (ko) 2001-04-25
CO5080764A1 (es) 2001-09-25
JP2001526224A (ja) 2001-12-18
PE20000042A1 (es) 2000-02-17
KR100700907B1 (ko) 2007-03-29
NO20003229D0 (no) 2000-06-21
NZ504928A (en) 2004-12-24
EP1041985B1 (en) 2006-02-15
CN1284875A (zh) 2001-02-21
HUP0102473A2 (hu) 2002-01-28
WO1999032114A1 (en) 1999-07-01
CZ20002236A3 (cs) 2001-04-11
ES2255196T3 (es) 2006-06-16
AR017440A1 (es) 2001-09-05

Similar Documents

Publication Publication Date Title
AP9700939A0 (en) Compounds and methods for the treatment of cancer
ZA971937B (en) Combinations for treatment of proliferative diseases.
PL330814A1 (en) Compounds for and methods of delivering pharmaceutical preparations and their application
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
IL136462A0 (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
EP1077704A4 (en) COMBINATION THERAPY FOR TREATING DEPRESSION
GB9812056D0 (en) Pharmaceutical composition for treatment of ibd and rbd
EP1139746A4 (en) CONNECTIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISEASES AND THE ADMINISTRATION OF MEDICINAL SUBSTANCES
IL136515A0 (en) Combination effective for the treatment of impotence
ZA989885B (en) Use of macrolides for the treatment of cancer and macular degeneration
ZA989556B (en) Benzoxazine derivatives their preparation and their therapeutic application
IL211081A0 (en) Methods and devices for providing prolonged drug therapy
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
HK1063004A1 (en) Oxalatoplatin and 5-fluorouracil for combination therapy of cancer
GB9808936D0 (en) Combination therapy for the prevention and treatment of osteoporosis
HUP0001263A3 (en) Methods of therapeutic administration of anti-cd4ol compounds
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
IL121329A0 (en) A pharmaceutical composition for the treatment of cancer
HUP9904173A3 (en) Pharmaceutical composition for treating viral diseases
GB2344586B (en) Isoquinuclidine derivatives,method of manufacturing the same and therapeutic agents for hypercholesterolemia containing these compounds
SG65766A1 (en) Composition for preventing and treating gingival diseases
ZA984650B (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
AU6126498A (en) Method for the treatment of drug addiction and homeopathic remedy
KR100248098B1 (en) Pharmaceutical composition for the treatment of dementia

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished